N/A N=442 Promoting Smoking Cessation in Carpenters
Smoking Cessation · Health Behavior · Cancer
Primary: Enrollment in Smoking Cessation Program — 5; 4 participants — p=0.76
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=84 A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
Ovarian Neoplasms
Primary: PFS Rate at 36 Weeks (After 9 Months) — 15.6; 2.9 percent probability of PFS
Phase 2 N=35 Meditation-CBT for Opioid-treated Chronic Low Back Pain
Chronic Pain · Low Back Pain
Primary: Health-Related Quality of Life: Averaged Pain Severity — -0.5; 0.4 units on a scale
Phase 2 N=30 Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer
Oropharyngeal Dysphagia · Oropharyngeal Cancer
Primary: Optimal Respiratory - Swallow Phase — 43; 86; 88.1 percentage of swallows
Phase 2 N=21 MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Colorectal Neoplasms
Primary: pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced…
Phase 1 N=64 A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Measured Serum Concentration (Cmax) for Serum Deferiprone and Deferiprone 3-O-glucuronide — 7.406; 17.835; 27.749; 36.644 μg/mL
Phase 3 N=17 Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
Peripheral Artery Disease · Hypertension
Primary: Peak Walking Time (PWT) — 110.4; -19.4 seconds — p=0.039
Phase 2 N=17 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
Atypical Hemolytic Uremic Syndrome
Primary: Platelet Count Change From Baseline to 26 Weeks — 65.18 10^9 cells/L — p=<0.0001
Phase 1 N=32 Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 15809; 10496; 10364; 437 ng/mL
N/A N=137 EUS-guided Fine Needle Aspiration (FNA) With and Without the Use of a Stylet
Biopsy, Fine-Needle · Biopsy, Fine-Needle/Methods · Endosonography
Primary: Compare Adequacy of Diagnoses in Passes With and Without a Stylet — 80; 68; 21; 18 passes
Phase 2 N=26 A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate — 87.5 percentage of participants — p=<0.0001
Phase 2 N=19 Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
Estrogen Receptor Positive · Male Breast Carcinoma · Progesterone Receptor Positive
Primary: Tumor Response Rate (Complete and Partial) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 1 participants
Phase 3 N=53 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Substance Withdrawal Syndrome
Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale
Phase 1 N=99 CBT With Disulfiram and Contingency Management
Cocaine Abuse
Primary: Change in Cocaine Use by Self Report — 72.2; 79.2; 91.1; 69.6 percentage of days abstinent
N/A N=198 Effects of Drainage in Laparoscopic Cholecystectomy
Acute Cholecystitis · Empyema of Gallbladder · Abscess of Gallbladder
Primary: Complication — 7; 7 participants